Literature DB >> 17060519

In vitro-clinical correlations for amphotericin B susceptibility in AIDS-associated cryptococcal meningitis.

R A Larsen1, M Bauer, A E Brouwer, A Sanchez, A M Thomas, A Rajanuwong, W Chierakul, S J Peacock, N Day, N J White, M G Rinaldi, T S Harrison.   

Abstract

Reliable measures of antifungal drug susceptibility are needed. We tested the susceptibility of Cryptococcus neoformans from patients treated with amphotericin B. In vitro susceptibility employed a modified broth macrodilution method. We demonstrate a strong correlation between the quantitative measures of in vitro amphotericin B susceptibility and the quantitative response observed in patients.

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 17060519      PMCID： PMC1797648          DOI： 10.1128/AAC.00742-06

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN： 0066-4804            Impact factor:   5.191


  9 in total

Review 1.  Antifungal susceptibility testing. New technology and clinical applications.

Authors:  M A Pfaller; W L Yu
Journal:  Infect Dis Clin North Am       Date:  2001-12       Impact factor: 5.982

2.  Combination antifungal therapies for HIV-associated cryptococcal meningitis: a randomised trial.

Authors:  Annemarie E Brouwer; Adul Rajanuwong; Wirongrong Chierakul; George E Griffin; Robert A Larsen; Nicholas J White; Thomas S Harrison
Journal:  Lancet       Date:  2004-05-29       Impact factor: 79.321

3.  Baseline correlation and comparative kinetics of cerebrospinal fluid colony-forming unit counts and antigen titers in cryptococcal meningitis.

Authors:  Annemarie E Brouwer; Paprit Teparrukkul; Supraphada Pinpraphaporn; Robert A Larsen; Wirongrong Chierakul; Sharon Peacock; Nicholas Day; Nicholas J White; Thomas S Harrison
Journal:  J Infect Dis       Date:  2005-07-07       Impact factor: 5.226

4.  Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome. National Institute of Allergy and Infectious Diseases Mycoses Study Group and AIDS Clinical Trials Group.

Authors:  C M van der Horst; M S Saag; G A Cloud; R J Hamill; J R Graybill; J D Sobel; P C Johnson; C U Tuazon; T Kerkering; B L Moskovitz; W G Powderly; W E Dismukes
Journal:  N Engl J Med       Date:  1997-07-03       Impact factor: 91.245

Review 5.  Development of interpretive breakpoints for antifungal susceptibility testing: conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and candida infections. Subcommittee on Antifungal Susceptibility Testing of the National Committee for Clinical Laboratory Standards.

Authors:  J H Rex; M A Pfaller; J N Galgiani; M S Bartlett; A Espinel-Ingroff; M A Ghannoum; M Lancaster; F C Odds; M G Rinaldi; T J Walsh; A L Barry
Journal:  Clin Infect Dis       Date:  1997-02       Impact factor: 9.079

6.  Results obtained with various antifungal susceptibility testing methods do not predict early clinical outcome in patients with cryptococcosis.

Authors:  E Dannaoui; M Abdul; M Arpin; A Michel-Nguyen; M A Piens; A Favel; O Lortholary; F Dromer
Journal:  Antimicrob Agents Chemother       Date:  2006-07       Impact factor: 5.191

7.  Correspondence of in vitro and in vivo fluconazole dose-response curves for Cryptococcus neoformans.

Authors:  Robert A Larsen; Madeline Bauer; Ann M Thomas; Alejandro Sanchez; Diane Citron; Meri Rathbun; Thomas S Harrison
Journal:  Antimicrob Agents Chemother       Date:  2005-08       Impact factor: 5.191

8.  Early mycological treatment failure in AIDS-associated cryptococcal meningitis.

Authors:  P A Robinson; M Bauer; M A Leal; S G Evans; P D Holtom; D A Diamond; J M Leedom; R A Larsen
Journal:  Clin Infect Dis       Date:  1999-01       Impact factor: 9.079

9.  Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis.

Authors:  Robert A Larsen; Madeline Bauer; Ann M Thomas; J Richard Graybill
Journal:  Antimicrob Agents Chemother       Date:  2004-03       Impact factor: 5.191
  9 in total
  5 in total

1.  Correlation of susceptibility of Cryptococcus neoformans to amphotericin B with clinical outcome.

Authors:  R A Larsen; M Bauer; P Pitisuttithum; A Sanchez; S Tansuphaswadikul; V Wuthiekanun; S J Peacock; A J H Simpson; A W Fothergill; M G Rinaldi; B Bustamante; A M Thomas; R Altomstone; N P J Day; N J White
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 2.  Physiological Differences in Cryptococcus neoformans Strains In Vitro versus In Vivo and Their Effects on Antifungal Susceptibility.

Authors:  Nina T Grossman; Arturo Casadevall
Journal:  Antimicrob Agents Chemother       Date:  2017-02-23       Impact factor: 5.191

3.  Cryptococcus neoformans: the model organism for yeast antifungal drug susceptibility testing.

Authors:  Madeline Bauer; Ann M Thomas; Robert A Larsen
Journal:  Mycopathologia       Date:  2012-02-10       Impact factor: 2.574

4.  Correlation of anti-fungal susceptibility with clinical outcomes in patients with cryptococcal meningitis.

Authors:  Chen-Hsiang Lee; Tzu-Yao Chang; Jien-Wei Liu; Fang-Ju Chen; Chun-Chih Chien; Ya-Fen Tang; Cheng-Hsien Lu
Journal:  BMC Infect Dis       Date:  2012-12-20       Impact factor: 3.090

5.  Major role for amphotericin B-flucytosine combination in severe cryptococcosis.

Authors:  Françoise Dromer; Claire Bernede-Bauduin; Didier Guillemot; Olivier Lortholary
Journal:  PLoS One       Date:  2008-08-06       Impact factor: 3.240
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.